[{"id":"9912c104-2619-4ba2-b95c-bb5c454672a9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04650451","created_at":"2021-01-19T20:40:10.787Z","updated_at":"2024-07-02T16:35:49.989Z","phase":"Phase 1/2","brief_title":"Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors","source_id_and_acronym":"NCT04650451","lead_sponsor":"Bellicum Pharmaceuticals","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temsirolimus • BPX-603"],"overall_status":"Suspended","enrollment":" Enrollment 220","initiation":"Initiation: 12/07/2020","start_date":" 12/07/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 01/02/2027","study_completion_date":" 01/02/2027","last_update_posted":"2023-04-20"}]